[ET Net News Agency, 8 December 2021] TOT BIOPHARM International Company Limited
(01875) said the company entered into the transfer agreement with Centerlab, pursuant to
which the company agreed to sell, and Centerlab agreed to purchase, the sale shares, being
1,000,000 Lumosa shares, at a price of NTD36.5 per Lumosa share for a total consideration
(excluding transaction costs) of NTD36,500,000 by way of an off-market block trade.
Lumosa Therapeutics is a clinical-stage biopharmaceutical company, dedicated to the
development of new drugs in the fields of neurological disorders, inflammatory diseases
and others. (RC)